ASCI Calls Out Misleading Claims in 60 Nutraceutical Ads
The Advertising Standards Council of India recently examined aggressive nutraceutical advertising claims across digital and print media. Consequently, an alarming 60 out of 61 evaluated campaigns breached the ASCI Code. Furthermore, the council highlighted substantial gaps in clinical substantiation across multiple brands. Therefore, healthcare providers in India must understand how these promotions distort patient expectations.
Scrutiny on Nutraceutical Advertising Claims and Gaps
Specifically, the investigation examined health advertisements between July and September 2026. While 29 advertisers accepted the findings immediately, 31 companies contested the complaints. However, none of these contesting brands could deliver robust evidence for their finished formulations. Instead, many companies relied only on isolated ingredient research rather than whole-product clinical trials. ASCI noted that ingredient data cannot validate the clinical efficacy of a finished supplement. In addition, several campaigns featured exaggerated before-and-after imagery to showcase miraculous transformations.
Clinical Conditions Targeted by Promotional Campaigns
Notably, many flagged promotions crossed the line into therapeutic claims for chronic medical conditions. For instance, brands promised rapid relief for asthma, chronic obstructive pulmonary disease, and hypertension. Other advertisements targeted polycystic ovary syndrome and elevated serum cholesterol levels. Furthermore, weight loss campaigns made rigid time-bound guarantees, such as losing six kilograms in two months. Consequently, such messaging blurs the vital distinction between dietary supplementation and medical treatment. Therefore, patients who trust unverified claims may delay or abandon prescribed medical therapies.
Implications for Clinical Practice and Patient Guidance
Physicians frequently encounter patients who purchase unregulated wellness supplements online. Hence, clinicians must proactively ask patients about their over-the-counter dietary supplement habits. Moreover, doctors can guide individuals to recognize unrealistic marketing promises and arbitrary timelines. Regulatory vigilance from ASCI protects consumer safety in a rapidly expanding wellness market. Nevertheless, physician vigilance remains the strongest shield against misleading health narratives.
Frequently Asked Questions
Q1: Why did ASCI flag these nutraceutical advertisements?
ASCI flagged the campaigns because manufacturers failed to provide adequate clinical substantiation for their health claims. Furthermore, many brands improperly used single-ingredient studies to validate finished products.
Q2: What specific medical claims did the report highlight?
The report highlighted claims regarding asthma, COPD, hypertension, hypercholesterolemia, and polycystic ovary syndrome. In addition, advertisements made unproven promises regarding rapid weight reduction and UV skin defense.
Q3: How should doctors advise patients regarding nutraceutical supplements?
Clinicians should advise patients to treat dietary supplements as supportive measures rather than disease cures. Consequently, patients must prioritize evidence-based medical treatment and consult their physicians before starting supplements.
References
- Advertising Standards Council flags misleading claims in nutraceutical ads - ETHealthworld
- A Pill for Thought: Review of Health and Wellness Claims in Nutraceutical Advertising - Advertising Standards Council of India (ASCI)
- ASCI report flags gaps in evidence for nutraceutical ad claims - afaqs!
